Cerity Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
JFG
Cerity Partners's XBI Position: Q2 2026 in Review
Cerity Partners reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 7.5% in Q2 2026, selling an estimated $326K and leaving 29,636 shares worth $4.69M. The position accounts for 0.01% of the portfolio, ranked #1132.
Cerity Partners first reported a position in XBI in Q1 2017 and has held it in 25 quarters since. The position peaked at $30.7M in Q1 2023. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Cerity Partners held 29,636 shares of State Street SPDR S&P Biotech ETF worth $4.69M as of Q2 2026.
- Cerity Partners sold 2,413 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $326K.
- State Street SPDR S&P Biotech ETF made up 0.01% of Cerity Partners's portfolio in Q2 2026, its #1132 holding.
- Cerity Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and has held it in 25 quarters since.
- Cerity Partners's State Street SPDR S&P Biotech ETF position peaked at $30.7M in Q1 2023.
- 936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.